MYCN and neuroblastoma: Aurora-A kinase inhibitors have been shown to effectively target MYCN amplified neuroblastoma by destabilizing N-Myc expression [8, 17], which is also the basis for exploring Aurora-A kinase inhibitors for the treatment of NEPC or N-Myc overexpressed CRPC (clinical trial #NCT01799278).